The compounds that demonstrated low biological effectiveness (IC50 above 55 μM) and clearly did not inhibit the cell profiling of a given cancer line were not analyzed for DNA damage, apoptosis, or PARP degradation. This evidence concerns the gene PARP1 and cancer.